Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial - The Lancet
nOPV2 was well tolerated and immunogenic in newborn infants, with two doses, at birth
and 4 weeks, resulting in almost 99% of infants having protective neutralising antibodies. - READ MORE
